NCT00988026

Brief Summary

This is a clinical trial to compare the benefits and possible adverse events of two antibiotic treatments for mild to moderate acne. It is expected that minocycline microgranules will be more effective than lymecycline with a better adverse events profile.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
168

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jun 2009

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2009

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

September 30, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 1, 2009

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2010

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2010

Completed
Last Updated

October 1, 2009

Status Verified

September 1, 2009

Enrollment Period

8 months

First QC Date

September 30, 2009

Last Update Submit

September 30, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of inflammatory and non-inflammatory acne lesions

    8 weeks

Secondary Outcomes (1)

  • Incidence of local and systemic adverse events

    8 weeks

Study Arms (2)

Minocycline 100 mg

EXPERIMENTAL

Minocycline

Drug: Minocycline vs Lymecycline

Lymecycline 300 mg

ACTIVE COMPARATOR

Group B: Lymecycline

Drug: Minocycline vs Lymecycline

Interventions

Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.

Lymecycline 300 mgMinocycline 100 mg

Eligibility Criteria

Age14 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Both gender
  • to 30 years old
  • Mild to moderate acne
  • Face localization
  • At least 20 non-inflammatory lesions OR
  • At least 15 inflammatory lesions OR
  • At least 30 total lesions AND
  • Less than 5 nodular lesions

You may not qualify if:

  • Patients younger than 14 or older than 30 years old
  • Less than 20 non-inflammatory lesions OR
  • Less than 15 inflammatory lesions OR
  • Less than 30 total lesions
  • Patients with severe acne
  • More than 5 nodular lesions OR
  • More than 50 inflammatory lesions OR
  • More than 125 total lesions
  • Pregnant women
  • Lactating women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Servicio de Dermatología. Hospital " Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León

Monterrey, Nuevo León, 64460, Mexico

RECRUITING

Related Publications (1)

  • Ocampo-Candiani J, Velazquez-Arenas LL, de la Fuente-Garcia A, Trevino-Gomezharper C, Berber A. Safety and efficacy comparison of minocycline microgranules vs lymecycline in the treatment of mild to moderate acne: randomized, evaluator-blinded, parallel, and prospective clinical trial for 8 weeks. J Drugs Dermatol. 2014 Jun;13(6):671-6.

Central Study Contacts

Luis Leobardo Velázquez-Arenas, MD

CONTACT

Jorge Ocampo-Candiani, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 30, 2009

First Posted

October 1, 2009

Study Start

June 1, 2009

Primary Completion

February 1, 2010

Study Completion

April 1, 2010

Last Updated

October 1, 2009

Record last verified: 2009-09

Locations